{"id":401713,"date":"2020-12-17T08:03:27","date_gmt":"2020-12-17T13:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401713"},"modified":"2020-12-17T08:03:27","modified_gmt":"2020-12-17T13:03:27","slug":"mersana-therapeutics-to-host-virtual-analyst-and-investor-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/","title":{"rendered":"Mersana Therapeutics to Host Virtual Analyst and Investor Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Dec.  17, 2020  (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET. The event will showcase the following agenda:\u00a0 \u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company\u2019s first-in-class ADC candidate targeting NaPi2b.<\/li>\n<li style=\"text-align:justify\">Mersana\u2019s management team will detail the Company\u2019s plans for the registration-enabling study of XMT-1536 in platinum-resistant ovarian cancer and outline its objectives for longer-term life cycle management studies to evaluate the potential of XMT-1536 in platinum-sensitive ovarian cancer.<\/li>\n<li style=\"text-align:justify\">Mersana\u2019s management team will disclose preclinical data supporting the development of the Company\u2019s first-in-class B7-H4 DolaLock ADC development candidate.<\/li>\n<li style=\"text-align:justify\">Mersana\u2019s management team will outline the Company\u2019s anticipated 2021 goals and milestones for its clinical and early-stage ADC programs.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Webcast and Conference Call Details<\/strong><br \/>\n        <br \/>A live webcast of the presentation will be available on the Investors &amp; Media section of the Mersana website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3HucNFncKCK9ddnufbjZGqd0VFmPSPR8835wG9pHyxAj1CIkbp1zGmyYKzyNDM8YFR4ZA32fA41kfvaqh2wAuqkvGTP3LXcFkyY2AZevPV23OOVadCHgS3v5MOuq69I1CYOX_QuXMRhEPD0Qor8n4mD94wsq1FVrEmCnGCaFiKk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.mersana.com\/events-and-presentations<\/a>. Analyst and Investors may ask a question during the live Q&amp;A by dialing (855) 940-5308 (toll-free domestic) or (929) 517-9745 (international) and providing the Conference ID 6265117.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Mersana Therapeutics<\/strong><br \/>\n        <br \/>Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana\u2019s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana\u2019s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana\u2019s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company\u2019s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company\u2019s Immunosynthen platform. In addition, multiple partners are using Mersana\u2019s Dolaflexin platform to advance their ADC pipelines.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Investor &amp; Media Contact<br \/>Sarah Carmody<br \/>617-844-8577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yQ4LmUFGfoE5A9or_Lxov1DmEL1UDOtNjVwiqyG4TjWCvN1iLkvmWDZEB_sWYIn0yupKnGAZ_d2M-NZrJ1Tx0vpXZM0MTV-wC-c8m46T3nY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">scarmody@mersana.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f88cf1c2-502e-4c3c-a14d-8cd8500e4499\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET. The event will showcase the following agenda:\u00a0 \u00a0 Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company\u2019s first-in-class ADC candidate targeting NaPi2b. Mersana\u2019s management &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mersana Therapeutics to Host Virtual Analyst and Investor Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401713","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET. The event will showcase the following agenda:\u00a0 \u00a0 Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company\u2019s first-in-class ADC candidate targeting NaPi2b. Mersana\u2019s management &hellip; Continue reading &quot;Mersana Therapeutics to Host Virtual Analyst and Investor Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T13:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mersana Therapeutics to Host Virtual Analyst and Investor Event\",\"datePublished\":\"2020-12-17T13:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/\"},\"wordCount\":409,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/\",\"name\":\"Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\",\"datePublished\":\"2020-12-17T13:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mersana Therapeutics to Host Virtual Analyst and Investor Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/","og_locale":"en_US","og_type":"article","og_title":"Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET. The event will showcase the following agenda:\u00a0 \u00a0 Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company\u2019s first-in-class ADC candidate targeting NaPi2b. Mersana\u2019s management &hellip; Continue reading \"Mersana Therapeutics to Host Virtual Analyst and Investor Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T13:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mersana Therapeutics to Host Virtual Analyst and Investor Event","datePublished":"2020-12-17T13:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/"},"wordCount":409,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/","name":"Mersana Therapeutics to Host Virtual Analyst and Investor Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=","datePublished":"2020-12-17T13:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzU4MCMzODgxMDk0IzIwODQwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-to-host-virtual-analyst-and-investor-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mersana Therapeutics to Host Virtual Analyst and Investor Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401713"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}